Ontology highlight
ABSTRACT:
SUBMITTER: Platzbecker U
PROVIDER: S-EPMC3306138 | biostudies-literature | 2012 Mar
REPOSITORIES: biostudies-literature
Platzbecker U U Wermke M M Radke J J Oelschlaegel U U Seltmann F F Kiani A A Klut I-M IM Knoth H H Röllig C C Schetelig J J Mohr B B Graehlert X X Ehninger G G Bornhäuser M M Thiede C C
Leukemia 20110902 3
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34(+) blood cells to pre-empt relapse in patients with CD34(+) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34(+) donor chimerism to <80% and received four azacitidine cycles (75 ...[more]